Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
This study aims to collect clinical data from adult patients with relapsed or refractory non-Hodgkin's lymphoma (r/r NHL) receiving cellular immunotherapy to establish a large database of cellular immunotherapy for Chinese patients.
| Condition(s) | Lymphoma, Non-Hodgkin |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study aims to collect clinical data from adult patients with relapsed or refractory non-Hodgkin's lymphoma (r/r NHL) receiving cellular immunotherapy to establish a large database of cellular immunotherapy for Chinese patients. |
| Who can participate | Inclusion Criteria: * Adult patients with a confirmed diagnosis of r/r B-NHL (including r/r DLBCL, r/r FL, r/r MCL, HGBL-NOS, FL3b, r/r MZL, transformed lymphomas such as MCL) and r/r T-cell lymphoma, who have received informed consent waivers; * Patients who have received or are receiving cellular immunotherapy, with cellular immunotherapy products including the following categories: cytokine-induced killer cell therapy (CIK), tumor-infiltrating lymphocytes (TIL), cytokine-induced killer cell-dendritic cell mixed therapy (DC-CIK), chimeric antigen receptor T cells, NK cells or macrophage therapy (CAR-T, CAR-NK, CAR-M), T-cell receptor chimeric T cell therapy (TCR-T), dendritic cell therapy. Exclusion Criteria: * NA |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Ruijin Hospital |
| Locations | Shanghai, China |
| Start date | 2024-05-15 |
| NCT ID | NCT06541327 |
| Official listing | https://clinicaltrials.gov/study/NCT06541327 |